Is High-Dose Growth Hormone Treatment during Puberty Worthwhile?
S. Cianfarani
DOI: https://doi.org/10.1159/000363108
2014-08-28
Hormone Research in Paediatrics
Abstract:of 2.4 cm) in the children treated with the higher dose, with no difference between the onceand twice-daily regimens. They conclude that the high-dose treatment regimen, due to high costs, should be limited to children who start replacement therapy late or who have more severe growth retardation at the onset of puberty. Although this is an original and well-designed study with potential clinical implications, it raises a number of issues which should be critically addressed. First, the diagnosis of GHD was based on the peak GH responses to two stimulation tests <10 μg/l and the ‘positive’ response to GH treatment, arbitrarily defined as a growth rate increase of at least 50% during the first year of therapy. The authors honestly admit that, with these criteria, their cohort may have included non-GH-deficient children. The age at the start of GH replacement (mean age of approx. 10 years), the IGF-I levels in the normal range (on average –1.2 SDS), the lack of information on pituitary MRI scan (presumably normal in the majority, if not all, of the patients) raise serious doubts about the GHD diagnosis. Rather, these features suggest a condition of a constitutional delay of growth and puberty onset, and the pharmacological therapy (rather than the replacement therapy) would explain the better results that were obtained with the higher dose. Moreover, sex steroid priming, to avoid false-positive GH responses secondary to delayed sex steroid surge [7] , was not performed. The rate of normalization of GH secretion at retesting after completion of growth is not reported. Almost two thirds of children Growth hormone (GH) production markedly increases during puberty, almost doubling the prepubertal circulating levels. This increase in mean levels occurs earlier in girls than in boys, is evident at night and is due to an increase in pulse amplitude rather than a change in pulse frequency [1] . This evidence has prompted some authors to mimic what occurs in physiology to test the efficacy of high-dose GH therapy in pubertal GH-deficient patients [2, 3] . It must be noted that reproducing the normal physiological patterns of GH secretion and activity is impossible with currently available modes and routes of administration of exogenous GH [4] . Nevertheless, preliminary results were indeed promising, showing a significant increase in pubertal height gain and near adult height [2, 3] . Subsequent divergent results [5] and the high cost-effectiveness ratio have limited the clinical application of this therapeutic approach. In this issue of Hormone Research in Paediatrics , Albertsson-Wikland et al. [6] report the favorable impact that high-dose GH treatment during puberty has on height gain and the adult height of children with idiopathic isolated GH deficiency (GHD). The authors conducted a nation-wide, multicenter, randomized, controlled trial, allocating the study cohort (111 intention-to-treat and 85 per-protocol patients) to three different treatment regimens at the onset of puberty: a standard dose (33 μg/kg/ day) or a double dose (67 μg/kg/day) injected once or twice daily. The results of this study show a significant increase in adult height (+0.4 SDS, corresponding to a mean Published online: August 28, 2014 HORMONE RESEARCH IN PÆDIATRICS